Boston Scientific Corp. (NYSE:BSX) has begun enrolling patients for a clinical trial of its "fourth-generation" drug-eluting coronary stent.
The new device, entitled the Synergy, has a bioabsorbable polymer and everolimus drug coating and the same alloy design used in the company’s Promus Element stent.
The trial, which will enroll 291 patients in Europe, Australia and New Zealand, compares the Synergy to BSX’s Promus stent in patients with a single de novo native coronary artery lesion, according to the company.
Boston Scientific designed the new stent to offer faster and more complete vessel healing after stent implantation than a conventional drug-eluting stent and provide the same level of restenosis reduction.
The principal investigators for the trial are Ian Meredith of Monash Medical Centre in Melbourne, Australia and Dr. Stefan Verheye of the Department of Interventional Cardiology, Middelheim Hospital in Antwerp, Belgium.
